Journal
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
Volume 42, Issue 1, Pages 113-122Publisher
AMER THORACIC SOC
DOI: 10.1165/rcmb.2008-0463OC
Keywords
NNK; PPAR gamma; troglitazone; HO-1; p21; NF-kappa B
Funding
- The Chinese University of Hong Kong [2006.1.085]
Ask authors/readers for more resources
Among the carcinogenic chemicals of cigarette smoking, 4-(methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) is the most potent. The activation of peroxisome proliferator-activated receptor (PPAR)gamma can arrest the growth of lung cancer. We hypothesized that PPAR gamma activation inhibits NNK-mediated proliferation of lung cancer cells. PPAR gamma expression was increased in 94.7% human lung cancer tumor tissues, compared with their paired corresponding nontumor tissues. PPAR gamma was also found to be abundant in all the lung cancer cell lines tested. Troglitazone dose-dependently inhibited the NNK-mediated proliferation of lung cancer cells that expressed PPAR gamma. Troglitazone blocked NNK-induced up-regulation of HO-1, Bcl-2, and c-IAP2, and recovered Bad activity that was suppressed by NNK. NNK promoted the nuclear p21, whereas troglitazone increased cytosolic p21. Troglitazone increased PPAR gamma transcriptional activity in NNK-treated cells and a PPAR gamma dominant-negative inhibitor completely suppressed the action of troglitazone, indicating that troglitazone against NNK was PPAR gamma-dependent. The findings reveal a novel molecular pathway of PPAR gamma activation against cigarette smoking-related lung cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available